Abstract 314P
Background
With the advent of targeted therapy, guidelines have expanded the eligibility criteria for gBRCA1/2 mutation testing. This study assessed RW BRCA1/2 testing rates (germline [g] +/- somatic [s]; s only; unknown test) in adult pts with HER2− ABC in France, Germany, Italy, and Spain (EU4), and Israel.
Methods
Oncologists abstracted data from medical charts for the next 8-10 consecutive pts with HER2− ABC in 2019/2020. Differences in demographics/clinical characteristics among BRCA1/2 tested/untested patients and BRCA1/2 testing rates were analyzed by t-tests and Fisher’s exact tests. BRCA1/2 testing was stratified by region (EU4, Israel), and hormone receptor (HR) status (HR+/HER2−, triple-negative breast cancer (TNBC)] and were compared via Fisher’s exact tests.
Results
Overall 265 oncologists provided data for 2,120 pts. Mean age was 62.5 years; tumor characteristics were: 87% HR+/HER2−, 13% TNBC. Compared with BRCA1/2 untested pts, BRCA1/2 tested pts were younger (57.7 vs. 66.7 yrs; P < 0.0001) and more likely to have a known family history of a BRCA-related cancer (36.6% vs. 10.6%; P < 0.0001). Across all countries, BRCA1/2 testing rates varied (34.6%–99.0%; Table). Lower BRCA1/2 testing rates were observed in EU4 vs. Israel; 41.8% (27.4% g+/-s; 9.7% s only; 4.7% unknown test) vs. 99.0% (95.9% g+/-s; 1.5% s only; 1.5% unknown test) (P < 0.0001).
Conclusions
In this study, disparities in BRCA1/2 mutation testing rates were observed. Focused efforts should be developed to increase oncologists’ awareness about the therapeutic relevance of gBRCA1/2 mutation testing, especially in EU4 countries. Table: 314P
| EU4 N=1926 | France N=525 | Germany N=428 | Italy N=516 | Spain N=457 | Israel N=194 | |
| All tested, N (%) | 805 (41.8) | 205 (39.0) | 192 (44.9) | 250 (48.4) | 158 (34.6) | 192 (99.0) |
| gBRCA1/2+/-sBRCA1/2 tested, N (%) | 528 (27.4) | 114 (21.7) | 131 (30.6) | 172 (33.3) | 111 (24.3) | 186 (95.9) |
| sBRCA1/2 only tested, N (%) | 186 (9.7) | 68 (13.0) | 40 (9.3) | 49 (9.5) | 29 (6.3) | 3 (1.5) |
| Unknown BRCA1/2, tested N (%) | 91 (4.7) | 23 (4.4) | 21 (4.9) | 29 (5.6) | 18 (3.9) | 3 (1.5) |
Clinical trial identification
Editorial acknowledgement
Medical writing support was provided by Ann Gordon, of CMC AFFINITY, McCann Health Medical Communications, and was funded by Pfizer.
Legal entity responsible for the study
Pfizer.
Funding
Pfizer.
Disclosure
M.P. Lux: Advisory/Consultancy, fees for non-CME services : Eli Lilly; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, fees for non-CME services : MSD; Advisory/Consultancy, fees for non-CME services : Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses, fees for non-CME services : Pfizer; Advisory/Consultancy, fees for non-CME services : Eisai; Advisory/Consultancy, fees for non-CME services : Genomic Health; Advisory/Consultancy, Travel/Accommodation/Expenses, fees for non-CME services : Roche; Leadership role, Officer/Board of Directors, Editorial board member: Medac; Advisory/Consultancy, fees for non-CME services : AstraZeneca; Honoraria (self): Hexal. A. Niyazov: Shareholder/Stockholder/Stock options, Full/Part-time employment: Pfizer Inc.. K. Lewis: Full/Part-time employment: Adelphi Real World. A. Rider: Full/Part-time employment: Adelphi Real World. B. Arondekar: Shareholder/Stockholder/Stock options, Full/Part-time employment: Pfizer Inc.. R. Mahtani: Research grant/Funding (self): Genentech; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Genentech; Advisory/Consultancy: Eisai; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Puma; Advisory/Consultancy: Amgen.